title: Optical Coherence Tomography Features in Diabetic Macular Edema and the Impact on Anti-VEGF Response.
abstract: OBJECTIVE
  To assess the relationship between spectral-domain optical coherence tomography (SD-OCT) features and functional outcomes for diabetic macular edema (DME) undergoing treatment with intravitreal bevacizumab (Avastin; Genentech, South San Francisco, CA).
  
  
  METHODS
  Institutional review board-approved, retrospective, consecutive case series of eyes receiving intravitreal bevacizumab (1.25 mg) for DME. SD-OCT features were evaluated and correlated with functional response to anti-vascular endothelial growth factor (VEGF) therapy.
  
  
  RESULTS
  One hundred fifty-nine eyes of 159 subjects were included in this study. Mean visual acuity improved from 20/76 to 20/58. The proportion of eyes with 20/40 or greater visual acuity increased with treatment (35% at initial visit, 51% at final visit). SD-OCT factors that were associated with functional outcomes to anti-VEGF therapy include ellipsoid zone integrity and severity of intraretinal fluid.
  
  
  CONCLUSIONS
  SD-OCT features appear to provide important markers for functional response to anti-VEGF therapy in DME. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:908-913.].
authors.forename: Yuji
authors.initials: Y
authors.lastname: Itoh
authors.forename: Daniel
authors.initials: D
authors.lastname: Petkovsek
authors.forename: Peter K
authors.initials: PK
authors.lastname: Kaiser
authors.forename: Rishi P
authors.initials: RP
authors.lastname: Singh
authors.forename: Justis P
authors.initials: JP
authors.lastname: Ehlers
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000068258:Bevacizumab / Q000008:administration & dosage*; D003930:Diabetic Retinopathy / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005544:Forecasting; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012160:Retina / Q000000981:diagnostic imaging*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence / Q000379:methods*; D042461:Vascular Endothelial Growth Factor A; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab